Latest Articlesddd
Bristol-Myers Squibb (BMY) will acquire Celgene (CELG) in a cash and stock transaction with an equity value of …
The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …
We have a few small clinical stage firms in the Prohost Portfolio that were established with the …
Gilead Sciences (GILD) and Scholar Rock Holding Corporation (SRRK) announced entering into a strategic collaboration to discover and develop …
We Wish You A Happy Spiritual Season and A Happy New Year 2019. We Hope that …
Agenus (AGEN) announced recently that it entered into an immuno-oncology (I-O) partnership with Gilead Sciences (GILD). …
Proteostasis (PTI) signed a worldwide, exclusive license agreement with Genentech about licensing rights to potential therapeutic small …
During the departed week, outstanding advancements and improvements in various clinical disciplines filled the media. What’s …
In the NEWS AstraZeneca (AZN) announced a collaboration with Cancer Research UK to launch a center …
The Chinese National Medical Products Administration (NMPA) has approved Gilead’s (GILD) HIV combination product Descovy®. In China, Descovy is …
Amgen Higher Dividends For those who invest in top-tier biotech firms for dividend payments, in addition …
The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …
Marinus Pharmaceuticals (MRNS) announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV), the …
Today, the market took another beating as a result of either an intentional or an unintentional …
Exelixis (EXEL) and Ipsen (Euronext: IPN; ADR: IPSEY) announced the initiation of COSMIC-312. A phase 3 pivotal trial of cabozantinib …
Another reason was found to hit the market when the economy is good and sustained and …
At the 60th American Society of Hematology (ASH) Annual Meeting CAR T is Still a Star With …
Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …
Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, …
Vertex Pharmaceuticals’ triple combination, which added the corrector VX-659 to the tezacaftor and ivacaftor combination, resulted …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
